Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02026063 · ClinicalTrials.gov registry record · Phase 3
Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms
A Phase 3 study, sponsored by Lexicon Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 124
- Enrollment target
NCT02026063: Completed Phase 3 study, sponsored by Lexicon Pharmaceuticals.
NCT02026063 is a Phase 3 study that has completed, run by Lexicon Pharmaceuticals. The registered enrollment target is 124 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (84% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02026063, a Phase 3 study, has completed, sponsored by Lexicon Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 124 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the long-term safety and tolerability of orally administered telotristat etiprate.
Primary Outcome
An adverse event (AE) is defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. An AE includes any noxious, pathological, or unintended change in anatomical, physiological, or metabolic functions as indicated by physical signs or symptoms occurring in any phase of the clinical study whether or not considered related to the study medication. A TEAE is an AE that occurs or worsens after receiving study drug.
Interventions
- DRUG Telotristat etiprate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2014-01-14 |
| Est. Completion | 2018-09-12 |
| Phase | Phase 3 |
What the finished NCT02026063 record still lists
NCT02026063 is an interventional study that assigns participants to a tested intervention. The registered 124 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (84% lower).
The record links to 0 conditions, and to 1 intervention - of which Telotristat etiprate is the first listed.
NCT02026063 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02026063 about?
NCT02026063 is a clinical study titled "Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms". The primary objective of this study is to evaluate the long-term safety and tolerability of orally administered telotristat etiprate.
What is the current status of trial NCT02026063?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 124 participants. The study started on 2014-01-14. Estimated completion is 2018-09-12.
What interventions are being tested in trial NCT02026063?
The interventions under investigation include: Telotristat etiprate (DRUG).
Who is sponsoring clinical trial NCT02026063?
This trial is sponsored by Lexicon Pharmaceuticals, which has 56 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02026063's enrollment target sits among peer trials
124 1610th of 2000 higher than 386 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523014 · 124 participants · Phase 2
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
- NCT02670707 · 124 participants · Phase 3
Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)
- NCT02830724 · 124 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
- NCT04748809 · 124 participants · NA
Effect of Anti-inflammatory Diet in Rheumatoid Arthritis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI